Abstract Objectives Most trials with Immune Checkpoint Inhibitors (ICIs) for Non-Small Cell
Lung Cancer (NSCLC) included only small subgroups of patients aged≥ 65. As NSCLC is …

Background The use of immune checkpoint inhibitors (ICIs) in the front-line treatment of
advanced non-small-cell lung cancer (NSCLC) is currently the standard of care. However …

Abstract Purpose Immune checkpoint inhibitors (ICIs) are an effective subsequent-line
treatment for patients with advanced non-small cell lung cancer (NSCLC). However, it …

Abstract Purpose Immune‐checkpoint inhibitors (ICIs) are effective against advanced non‐
small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in …

Importance Immune checkpoint inhibitor (ICI) plus chemotherapy combination treatment (ICI-
chemotherapy) is now a standard treatment for non–small cell lung cancer (NSCLC) without …

OBJECTIVE To evaluate the efficacy and toxicity of immune checkpoint inhibitors (ICIs) in
older patients with advanced non–small cell lung cancer (NSCLC) seen in routine clinical …

Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape
among non-small-cell lung cancer (NSCLC) patients. The efficacy of ICI therapy in older …

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung
cancer (NSCLC) accounts for approximately 80% of all lung cancers, and most NSCLC is …

Background Limited data exist regarding the characteristics and survival outcomes of older
adults with non–small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors …

Background: Despite the acknowledged benefits of immune checkpoint inhibitor (ICI)-based
combination therapy (either with other checkpoint inhibitors, chemotherapy, targeted …